Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) EBITDA Margin (2016 - 2020)

Syndax Pharmaceuticals has reported EBITDA Margin over the past 6 years, most recently at 5226.32% for Q4 2020.

  • Quarterly results put EBITDA Margin at 5226.32% for Q4 2020, down 148816.0% from a year ago — trailing twelve months through Dec 2020 was 4708.17% (down 91523.0% YoY), and the annual figure for FY2025 was 158.45%, up 127598.0%.
  • EBITDA Margin for Q4 2020 was 5226.32% at Syndax Pharmaceuticals, roughly flat from 5238.26% in the prior quarter.
  • Over the last five years, EBITDA Margin for SNDX hit a ceiling of 1633.61% in Q4 2017 and a floor of 5238.26% in Q3 2020.
  • Median EBITDA Margin over the past 5 years was 4327.19% (2017), compared with a mean of 4199.42%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 3386552bps in 2016 and later crashed -345402bps in 2018.
  • Syndax Pharmaceuticals' EBITDA Margin stood at 3652.79% in 2016, then skyrocketed by 55bps to 1633.61% in 2017, then crashed by -211bps to 5087.63% in 2018, then increased by 27bps to 3738.16% in 2019, then crashed by -40bps to 5226.32% in 2020.
  • The last three reported values for EBITDA Margin were 5226.32% (Q4 2020), 5238.26% (Q3 2020), and 4382.59% (Q2 2020) per Business Quant data.